Leap Therapeutics gets FDA orphan status for DKN-01 for gastric and gastroesophageal junction cancer
US immuno-oncology company Leap Therapeutics has been granted orphan drug designation for DKN-01 from the US Food and Drug Administration (FDA) for the treatment of gastric and gastroesophageal junction cancer. DKN-01, which is a humanized monoclonal antibody, has been designed to bind to and block the activity of the Dickkopf-1 (DKK1) protein, a modulator of […]